Oncology, cardiovascular, autoimmune/anti-inflammatories, and infectious
diseases will be the top areas of investments in 2015, according to Frost & Sullivan. Pharma companies will also be keen to invest in in-vitro diagnostics such
as biomarkers; molecular, tissue, companion diagnostics; predisposition
disease; and predictive testing, added the company's Life Sciences Global
Program Director, Jennifer Lazar.
Frost & Sullivan has released its "Drug Launch and Phase 3 Trial
Watch List for Top Therapy Areas for 2015". It includes:
- Puma Biotechnology’s tyrosine kinase inhibitor, neratinib, for breast cancer adjuvant therapy.
- Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, nivolumab, for previously treated advanced melanoma patients.
- Novartis’ selective IL-17A inhibitor, secukinumab, for the treatment of plaque psoriasis.
- Novartis’ angiotensin receptor neprilysin inhibitor (ARNi), LCZ696, for the treatment of heart failure.
- AbbVie’s ABT-450/ritonavir co-formulated with ombitasvir (ABT-267), and dasabuvir (ABT-333) with or without ribavirin for the treatment of hepatitis C.
- GlaxoSmithKline’s RTS,S vaccine is expected to be the first malaria vaccine in the market.
- Sanofi Pasteur's Dengue Vaccine.
In addition to new molecular entity product launches, Frost & Sullivan
reports that there are "abundant opportunities for generic and biosimilar
drugs due to the patent expiry of several blockbuster drugs in 2014 and
2015". Some of
those include:
- Otsuka Pharmaceutical’s Abilify (anti-psychotic)
- Teva Pharmaceutical’s Copaxone (relapse-remitting multiple sclerosis)
- Novartis’ Gleevec (chronic myeloid leukemia)
- Forest Laboratories’ Namenda (Alzheimer’s disease)
- Pfizer’s Zyvox (anti-viral) and,
- GlaxoSmithKline’s Avodart (benign prostatic hyperplasia)
Φαρμακευτικό Μάρκετινγκ: Θεωρία, Πρακτική, Δεοντολογία
The
ultimate guide for Pharma Marketing Champions
Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…